MentionFox
Home › Stakes › Starling Oncology, Inc.
5%+ stakes · Schedule 13D and 13G

Starling Oncology, Inc.: 5%+ holders

Before you sign with, sell to or invest in Starling Oncology, Inc.

MentionFox check on Starling Oncology, Inc.: no red flags found in 7 sources (checked 15 November 2026). mentionfox.com/c/stakes/starling-oncology

Check Starling Oncology, Inc. before you sign, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Starling Oncology, Inc.?

Who has reported owning 5% or more of Starling Oncology, Inc., from Schedule 13D and 13G filings: each holder's stake as filed, the timeline, and the purpose each 13D states, quoted.

As of November 15, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Starling Oncology, Inc. The largest reported stake is Chernett Jorey's, at 5.6%. 6 filings are on record since September 5, 2025 (Schedule 13G/A, November 13, 2026).

Chernett Jorey also filed stake reports on 16 other companies ↓

Sell to companies like Starling Oncology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Key facts

  • · Holder: Chernett Jorey · Percent: 5.6% · Shares: 5,934,872 · SCHEDULE 13G/A
  • · Reporting person: M33 Growth I L.P. · Sole voting: 0 · Shared voting: 5,002,656 · Sole dispositive: 0 · Shared dispositive: 5,002,656 · SCHEDULE 13D/A, 2026-05-15
  • · Holder: Chernett Jorey · Percent: 10.2% · SCHEDULE 13G/A
  • · Holder: Chernett Jorey · Percent: 5.2% · SCHEDULE 13G
  • · Holder: M33 Growth I LP · Percent: 5.46% · SCHEDULE 13D/A
At 5% or more1
Filings6
Latest filing2026-11-13

Starling Oncology, Inc. has 6 Schedule 13D or 13G filings on record since 2025-09-05. 1 holder's latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

HolderPercentSharesLatestEvent date
5.6%5,934,872SCHEDULE 13G/A, 2026-11-132026-11-13
M33 Growth I L.P.4.94%5,002,656SCHEDULE 13D/A, 2026-05-152026-05-14

Holding shares or following this stake? See who's behind Starling Oncology, Inc. and the warning signs.

Free to see. No signup.

Keep reading

More on Starling Oncology, Inc. and the records around it.

Starling Oncology, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Starling Oncology, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Starling Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Starling Oncology, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    7 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Chernett Jorey5,934,87205,934,8720SCHEDULE 13G/A, 2026-11-13
M33 Growth I L.P.05,002,65605,002,656SCHEDULE 13D/A, 2026-05-15
M33 Growth I GP LLC05,002,65605,002,656SCHEDULE 13D/A, 2026-05-15
Toi M, LLC0000SCHEDULE 13D/A, 2026-05-15

The latest filing identifies Starling Oncology, Inc. by CUSIP 30068X103 and gives its principal executive office as 18000 STUDEBAKER RD, SUITE 800, CERRITOS, CA 90703 (SCHEDULE 13G/A, 2026-11-13).

What the percentages are based on

The aggregate percentage of Shares owned by the Reporting Person is based upon 101,991,024 Shares outstanding as of [date], as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the U.S.Chernett Jorey, SCHEDULE 13G/A, 2026-11-13

Source of funds (Item 3)

Between May 8, 2026 and May 14, 2026, M33 LP sold an aggregate of 1,800,000 shares in open market transactions on Nasdaq.M33 Growth I L.P., SCHEDULE 13D/A, 2026-05-15

Purpose of Transaction (Item 4)

M33 Growth I L.P.

Item 4 is hereby supplemented as follows: The information set forth in Item 3 of this Schedule 13D, as amended therein, is incorporated herein by reference.Item 4 of the SCHEDULE 13D/A filed 2026-05-15

Timeline

FiledHolderPercentFiling
2025-09-05M33 Growth I LP9.79%SCHEDULE 13D/A
2025-11-20M33 Growth I LP5.46%SCHEDULE 13D/A
2026-01-15Chernett Jorey5.2%SCHEDULE 13G
2026-03-16Chernett Jorey10.2%SCHEDULE 13G/A
2026-05-15M33 Growth I L.P.4.94%SCHEDULE 13D/A
2026-11-13Chernett Jorey5.6%SCHEDULE 13G/A

Questions about who owns Starling Oncology, Inc.

Who owns Starling Oncology, Inc.?

On this page, one holder's latest ownership filing reports 5% or more of Starling Oncology, Inc.: Chernett Jorey (5.6%, Schedule 13G/A, filed 2026-11-13).

When did Chernett Jorey buy into Starling Oncology, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Chernett Jorey on this page is the Schedule 13G, filed 2026-01-15, reporting 5.2%; its latest, Schedule 13G/A filed 2026-11-13, reports 5.6%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Starling Oncology, Inc.

DateRecordFigureOur pageSource
April 8, 2025Form D, private offering$16.44M soldForm D pageSource

Tools for this story

Each opens in a new tab, filled in for Starling Oncology, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/stakes/starling-oncology
Last updated 2026-11-15
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Who owns 5% or more of Starling Oncology, Inc.? 1 holder at 5% or more, largest Chernett Jorey 5.6%. MentionFox, 2026-11-15. https://mentionfox.com/stakes/starling-oncology